Wuxi AppTec and Pfizer contributed to a series A round that will support progress of Simcha Therapeutics' immuno-oncology treatments toward clinical trials.

Simcha Therapeutics, a US-based cancer therapeutics developer spun out of Yale University, has received $25m of series A funding from investors including pharmaceutical firms Pfizer and WuXi AppTec.

The round also featured venture capital firm Sequoia Capital China and Connecticut Innovations, the strategic venturing arm of the US state of Connecticut, while WuXi AppTec invested through its Corporate Venture Fund.

Founded in 2018, Simcha is engineersing cytokine molecules that will form the basis for cancer immunotherapies. Its lead candidate, ST-067,…